deltatrials
Active Not Recruiting PHASE2 NCT01723774

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination With Anastrozole in Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Sponsor: Pfizer

Conditions Breast Neoplasms
Interventions Anastrozole Goserelin PD0332991 Surgery (standard of care) Tumor biopsy
Updated 20 times since 2017 Last updated: Dec 2, 2025 Started: Apr 10, 2013 Primary completion: Apr 13, 2021 Completion: Aug 24, 2026

A PHASE2 clinical study on Breast Neoplasms, this trial is ongoing. The trial is conducted by Pfizer and has accumulated 20 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Jun 2019 · 7 months · monthly snapshot~Jun 2019 – ~Dec 2019 · 6 months · monthly snapshot~Dec 2019 – ~Aug 2020 · 8 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jan 2023 · 2 months · monthly snapshot~Jan 2023 – ~Jan 2024 · 12 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 3 months · monthly snapshot

Change History

20 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 15 earlier versions

  1. Jan 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Sep 2021 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  8. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  9. Dec 2019 — Aug 2020 [monthly]

    Recruiting PHASE2

  10. Jun 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  11. Nov 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

  12. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  13. Jul 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  14. Feb 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

  15. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
  • Washington University School of Medicine
Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations